Sunshine Biopharma, Inc. (SBFMW)Fort Lauderdale, United States | NasdaqCM
0.03 USD
|
Hot Take ↕ | Oct. 10, 2026, 10:27 a.m. EDT
The security is trading at a fraction of its book value due to severe operational distress, making it a speculative contrarian play rather than a standard investment. Fundamentals are deteriorating sharply with negative revenue growth, significant losses across all margin lines, and negative free cash flow, indicating the business is burning capital without generating returns. The balance sheet shows a concerning debt-to-equity ratio relative to the tiny market cap, and the lack of any price history or analyst coverage suggests extreme liquidity risk. With no dividend to provide income and a trajectory of shrinking revenues, the long-term outlook is bleak, while the short-term outlook remains bearish given the absence of any catalyst to reverse the decline. |
| Attribute | Value |
|---|---|
| Debt to Equity Ratio | 2.463 |
| Revenue per Share | 49.666 |
| Beta | 1.35 |
| Profit Margins | -16.50% |
| Website | https://sunshinebiopharma.com |
| Attribute | Value |
|---|---|
| Address1 | 333 Las Olas Way |
| Address2 | CU4 Suite 433 |
| Ask | 0.0 |
| Ask Size | 0 |
| Beta | 1.354 |
| Bid | 0.0 |
| Bid Size | 0 |
| Book Value | 11.524 |
| City | Fort Lauderdale |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.0251 |
| Current Ratio | 5.457 |
| Custom Price Alert Confidence | HIGH |
| Day High | 0.0251 |
| Day Low | 0.0251 |
| Debt To Equity | 2.463 |
| Ebitda | -4,848,974 |
| Ebitda Margins | -0.13718 |
| Eps Trailing Twelve Months | -2.214 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Two Week High | 0.0251 |
| Fifty Two Week High Change | 0.0 |
| Fifty Two Week High Change Percent | 0.0 |
| Fifty Two Week Low | 0.0251 |
| Fifty Two Week Low Change | 0.0 |
| Fifty Two Week Low Change Percent | 0.0 |
| Fifty Two Week Range | 0.0251 - 0.0251 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,784,295,000,000 |
| Float Shares | 2,899,938 |
| Free Cashflow | -2,011,131 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 50 |
| Fullday Change | 0.0 |
| Fullday Change Percent | 0.0 |
| Fullday Price | 0.0251 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.303 |
| Gross Profits | 10,710,057 |
| Has Pre Post Market Data | 1 |
| Industry | |
| Industry Key | |
| Ipo Expected Date | 2,022-02-15 |
| Language | en-US |
| Long Business Summary | Sunshine Biopharma, Inc. operates as a pharmaceutical company that engages in the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, dermatology, smoking cessation, cholelithiasis, anticonvulsant, urology, women's health, acid reflux, and anticonvulsant indications. Sunshine The company is based in Fort Lauderdale, Florida. |
| Long Name | Sunshine Biopharma, Inc. |
| Market | us_market |
| Market State | POST |
| Max Age | 86,400 |
| Message Board Id | finmb_78729055 |
| Net Income To Common | -5,832,664 |
| Open | 0.2428 |
| Operating Cashflow | -5,352,750 |
| Operating Margins | -0.17411 |
| Phone | 954 330 0684 |
| Previous Close | 0.0251 |
| Price Hint | 4 |
| Price To Book | 0.0021780632 |
| Profit Margins | -0.16500999 |
| Quick Ratio | 3.215 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.0 |
| Regular Market Change Percent | 0.0 |
| Regular Market Day High | 0.0251 |
| Regular Market Day Low | 0.0251 |
| Regular Market Day Range | 0.0251 - 0.0251 |
| Regular Market Open | 0.2428 |
| Regular Market Previous Close | 0.0251 |
| Regular Market Price | 0.0251 |
| Regular Market Time | 1,792,074,815 |
| Regular Market Volume | 1,790 |
| Return On Assets | -0.09906 |
| Return On Equity | -0.21917999 |
| Revenue Growth | -0.016 |
| Revenue Per Share | 49.666 |
| Sand P52 Week Change | 0.16207206 |
| Sector | |
| Sector Key | |
| Short Name | Sunshine Biopharma Inc. warrant |
| Source Interval | 15 |
| State | FL |
| Symbol | SBFMW |
| Total Cash | 14,029,781 |
| Total Cash Per Share | 3.618 |
| Total Debt | 678,338 |
| Total Revenue | 35,346,772 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.214 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Type Disp | Equity |
| Volume | 1,790 |
| Website | https://sunshinebiopharma.com |
| Zip | 33,301 |